# **Quality Performance Indicators Audit Report**

| Tumour Area:        | Endometrial Cancer   |  |  |  |
|---------------------|--|--|--|--|
| Patients Diagnosed: | 1 <sup>st</sup> October 2020 – 30 <sup>th</sup> September 2021 |  |  |  |
| Published Date:     | 8th February 2023  |  |  |  |



## 1. Patient Numbers and Case Ascertainment in the North of Scotland


Between 1<sup>st</sup> October 2020 and 30<sup>th</sup> September 2021, a total of 194 cases of endometrial cancer were diagnosed in the North of Scotland and recorded through audit Overall case ascertainment was 97%, and QPI calculations based on data captured are considered to be representative of patients diagnosed with cervical cancer during the audit period.

| Case ascertainment and proportion of NoS total for patients diagnosed with endometrial cancer in 2020-202 | 21 |
|---|----|
|---|----|

|                                 | Grampian | Highland | Orkney | Shetland | Tayside | W Isles | NoS  |
|---------------------------------|----------|----------|--------|----------|---------|---------|------|
| No. of Patients 2020-21         | 74       | 46       | 3      | 5        | 61      | 5       | 194  |
| % of NoS total                  | 38%      | 24%      | 2%     | 3%       | 31%     | 3%      | 100% |
| Mean PHS Cases 2016-20          | 82       | 39       | 3      | 3        | 67      | 5       | 199  |
| % Case ascertainment<br>2016-20 | 90%      | 118%     | 100%   | 167%     | 91%     | 100%    | 97%  |

## 2. Age Distribution

The figure below shows the age distribution of patients diagnosed with endometrial cancer in the North of Scotland in 2020-21, with numbers highest in the 70-74 years age bracket.



### Patient age at time of diagnosis

Age distribution of patients diagnosed with endometrial cancer in the North of Scotland in 2020-2021.

## 3. Performance against Quality Performance Indicators (QPIs)

Definitions for the QPIs reported in this section are published by Health Improvement Scotland<sup>1</sup>, while further information on datasets and measurability used are available from Public Health Scotland<sup>2</sup>. Data for most QPIs are presented by Board of diagnosis; however QPI 4 and QPI 7 are presented by hospital of surgery. In addition, QPI 8, clinical trials and research study access, is reported by NHS Board of residence.

\*Where the number of cases per Board is between one and four, results have been excluded from charts and tables to minimise the risk of disclosure. However, all board results are included within the total for the North of Scotland.

### 4. Governance and Risk

QPI performance is overseen by the North Cancer Alliance and its constituent groups, with an assessment of clinical risk and action planning undertaken collaboratively and reporting at board and regional level. Actions will be overseen by the Pathway Boards and reported concurrently into the NCA governance groups and the Clinical Governance committees at each North of Scotland health board.

Further information is available <u>here</u>.

### QPI 1 Radiological Staging


Proportion of patients with endometrial cancer who have an MRI and/or CT scan of the abdomen and pelvis performed prior to definitive treatment.




### QPI 2 Multidisciplinary Team Meeting (MDT)

Proportion of patients with endometrial cancer who are discussed at a MDT meeting before definitive treatment.







This QPI was narrowly missed by the North of Scotland due to a variety of clinical reasons linked to disease progression and patient fitness.


# QPI 4 Laparoscopic Surgery Proportion of patients with endometrial cancer undergoing definitive surgery who undergo laparoscopic surgery.



### QPI 5


### Adjuvant Radiotherapy

Proportion of patients with stage IB, grade 1 or 2, or stage IA, grade 3 endometrioid or mucinous endometrial cancer having adjuvant radiotherapy.



# QPI 6 Systemic Anti Cancer Therapy (SACT) / Hormone Therapy

Proportion of patients with stage IV endometrial cancer receiving SACT or hormone therapy.



North of Scotland did not meet this QPI. Patients of stage IV endometrial cancer were not offered SACT or hormone therapy as they were deemed to be fit for best supportive care only.

### QPI 7

## 30 Day Mortality Following Surgery

Proportion of patients with endometrial cancer who die within 30 days of surgery for endometrial cancer.



### References

1. Endometrial Cancer Clinical Performance Indicators, Version 4.0 Health Improvement Scotland. <u>https://www.healthcareimprovementscotland.org/our\_work/cancer\_care\_improvement/cancer\_qpis/quali</u> ty\_performance\_indicators.aspx

2. Public Health Scotland -

https://www.isdscotland.org/Health-Topics/Cancer/Cancer-Audit/#background